BACKGROUND A patient-derived organoid (PDO) platform may serve as a promising tool for translational cancer research. In this study, we evaluated PDO’s ability to predict clinical response to gastrointestinal (GI) cancers.METHODS We generated PDOs from primary and metastatic lesions of patients with GI cancers, including pancreatic ductal adenocarcinoma, colorectal adenocarcinoma, and cholangiocarcinoma. We compared PDO response with the observed clinical response for donor patients to the same treatments.RESULTS We report an approximately 80% concordance rate between PDO and donor tumor response. Importantly, we found a profound influence of culture media on PDO phenotype, where we showed a significant difference in response to standard-of-care chemotherapies, distinct morphologies, and transcriptomes between media within the same PDO cultures.CONCLUSION While we demonstrate a high concordance rate between donor tumor and PDO, these studies also showed the important role of culture media when using PDOs to inform treatment selection and predict response across a spectrum of GI cancers.TRIAL REGISTRATION Not applicable.FUNDING The Joan F. & Richard A. Abdoo Family Fund in Colorectal Cancer Research, GI Cancer program of the Mayo Clinic Cancer Center, Mayo Clinic SPORE in Pancreatic Cancer, Center of Individualized Medicine (Mayo Clinic), Department of Laboratory Medicine and Pathology (Mayo Clinic), Incyte Pharmaceuticals and Mayo Clinic Hepatobiliary SPORE, University of Minnesota-Mayo Clinic Partnership, and the Early Therapeutic program (Department of Oncology, Mayo Clinic).
Tara L. Hogenson, Hao Xie, William J. Phillips, Merih D. Toruner, Jenny J. Li, Isaac P. Horn, Devin J. Kennedy, Luciana L. Almada, David L. Marks, Ryan M. Carr, Murat Toruner, Ashley N. Sigafoos, Amanda N. Koenig-Kappes, Rachel L.O. Olson, Ezequiel J. Tolosa, Cheng Zhang, Hu Li, Jason D. Doles, Jonathan Bleeker, Michael T. Barrett, James H. Boyum, Benjamin R. Kipp, Amit Mahipal, Joleen M. Hubbard, Temperance J. Scheffler Hanson, Gloria M. Petersen, Surendra Dasari, Ann L. Oberg, Mark J. Truty, Rondell P. Graham, Michael J. Levy, Mojun Zhu, Daniel D. Billadeau, Alex A. Adjei, Nelson Dusetti, Juan L. Iovanna, Tanios S. Bekaii-Saab, Wen Wee Ma, Martin E. Fernandez-Zapico
Title and authors | Publication | Year |
---|---|---|
The impact of extracellular matrix on the precision medicine utility of pancreatic cancer patient-derived organoids
Jan Lumibao, Shira R Okhovat, Kristina L Peck, Xiaoxue Lin, Kathryn Lande, Jingjing Zou, Dannielle Engle |
JCI Insight | 2024 |
Rebuilding the microenvironment of primary tumors in humans: a focus on stroma
Mun S, Lee HJ, Kim P |
Experimental & molecular medicine | 2024 |
Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma.
Desai A, Xiao AH, Choi D, Toruner MD, Walden D, Halfdanarson TR, Alberts S, McWilliams RR, Mahipal A, Ahn D, Babiker H, Stybayeva G, Revzin A, Kizilbash S, Adjei A, Bekaii-Saab T, Mansfield AS, Carr RM, Ma WW |
Cancers | 2024 |
Building consensus on the application of organoid-based drug sensitivity testing in cancer precision medicine and drug development
Xiang D, He A, Zhou R, Wang Y, Xiao X, Gong T, Kang W, Lin X, Wang X, Liu L, Chen YG, Gao S, Liu Y |
Theranostics | 2024 |
XENTURION is a population-level multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patients
Leto SM, Grassi E, Avolio M, Vurchio V, Cottino F, Ferri M, Zanella ER, Borgato S, Corti G, di Blasio L, Somale D, Vara-Messler M, Galimi F, Sassi F, Lupo B, Catalano I, Pinnelli M, Viviani M, Sperti L, Mellano A, Ferrero A, Zingaretti CC, Puliafito A, Primo L, Bertotti A, Trusolino L |
Nature Communications | 2024 |
Comparative Analysis of Commercial and Home-Made Media on RSPO1/S6R Axis in Organoids with Different Wnt Backgrounds: A Methodological Guide for the Selection of Intestinal Patient-Derived Organoids Culture Media.
Calafato G, Alquati C, Bernardi A, Di Paola FJ, Ricciardiello L |
International journal of molecular sciences | 2024 |
Strategic insights into the cultivation of pancreatic cancer organoids from endoscopic ultrasonography-guided biopsy tissue.
Yang JL, Zhang JF, Gu JY, Gao M, Zheng MY, Guo SX, Zhang T |
World journal of gastroenterology | 2024 |
Novel Uveal Melanoma Patient-Derived Organoid Models Recapitulate Human Disease to Support Translational Research
Dalvin LA, Andrews-Pfannkoch CM, Miley DR, Hogenson TL, Erickson SA, Malpotra S, Anderson KJ, Omer ME, Almada LL, Zhang C, Li H, Salomao DR, Shields CL, Lally SE, Malsch RM, Armitage JA, Holmes HL, Romero MF, Fautsch MP, Markovic SN, Fernandez-Zapico ME |
Investigative Ophthalmology & Visual Science | 2024 |
Patient-derived tumor organoids: A preclinical platform for personalized cancer therapy
Taurin S, Alzahrani R, Aloraibi S, Ashi L, Alharmi R, Hassani N |
Translational Oncology | 2024 |
KRASG 12C ‐inhibitor‐based combination therapies for pancreatic cancer: insights from drug screening
Tapia Contreras C, Falke JD, Seifert D, Schneider C, Krauß L, Fang X, Müller D, Demirdizen E, Spitzner M, De Oliveira T, Schneeweis C, Gaedcke J, Kaulfuß S, Mirzakhani K, Wollnik B, Conrads K, Beißbarth T, Salinas G, Hügel J, Beyer N, Rheinländer S, Sax U, Wirth M, Conradi L, Reichert M, Ellenrieder V, Ströbel P, Ghadimi M, Grade M, Saur D, Hessmann E, Schneider G |
Molecular Oncology | 2024 |
Organoid‐based precision medicine in pancreatic cancer
Beutel AK, Ekizce M, Ettrich TJ, Seufferlein T, Lindenmayer J, Gout J, Kleger A |
United European Gastroenterology Journal | 2024 |